StoneX Group’s Heron Therapeutics HRTX Stock Holding History

StoneX Group’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,809	Closed	-$24.5K	–	1063
2025 Q4	$24.5K	Buy	+18,809	New	+$23.2K	﹤0.01%	963

Other funds holding HRTX

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

StoneX Group's HRTX Position: Q1 2026 in Review

StoneX Group sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 18,809 shares — an estimated $24.5K sold.

StoneX Group first reported a position in HRTX in Q4 2025 and held it in 1 quarter. The position peaked at $24.5K in Q4 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

StoneX Group reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
StoneX Group sold 18,809 Heron Therapeutics shares in Q1 2026, an estimated $24.5K.
StoneX Group first reported a position in Heron Therapeutics in Q4 2025 and held it in 1 quarter.
StoneX Group's Heron Therapeutics position peaked at $24.5K in Q4 2025.
167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.